High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
103.37M
+14.42%
--
--
113.77M
+21.78%
--
--
155.16M
+48.56%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Insmed Incorporated (INSM) for FY2025, with the revenue forecasts being adjusted by -1.58% over the past three months. During the same period, the stock price has changed by 29.35%.
Revenue Estimates for FY2025
Revise Downward
-1.58%
In Past 3 Month
Stock Price
Go Up
+29.35%
In Past 3 Month
17 Analyst Rating
0Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 109.69 USD with a low forecast of 90.00 USD and a high forecast of 124.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy
0Current: 102.680
Low
90.00
Averages
109.69
High
124.00
0Current: 102.680
Low
90.00
Averages
109.69
High
124.00
Stifel
Stephen Willey
Buy
maintain
$92 -> $110
2025-06-11
Reason
Stifel
Stephen Willey
Price Target
$92 -> $110
2025-06-11
maintain
Buy
Reason
Stifel analyst Stephen Willey raised the firm's price target on Insmed to $110 from $92 and keeps a Buy rating on the shares. The firm believes Phase 2 TPIP data in pulmonary arterial hypertension demonstrating an "unprecedented" PVR reduction accompanied by "unambiguously-clear and clinically-meaningful" improvements across multiple secondary endpoints represents "an important step" on the company's path to "making the leap to large-cap status," the analyst tells investors. This TPIP data provides an important valuation tailwind ahead of a pending brensocatib approval and launch and "will also likely reignite the topic of strategic optionality," the analyst added.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$90 -> $120
2025-06-11
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$90 -> $120
2025-06-11
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Insmed to $120 from $90 and keeps a Buy rating on the shares. The firm says investors have now seen the positive Phase 2A and Phase 2B studies from Insmed for treprostinil palmitil inhalation powder in pulmonary arterial hypertension patients. The firm believes successful Phase 2 progress across endpoints in PAH development has "overwhelmingly translated positively to Phase 3 and subsequent FDA approval."
Wells Fargo
NULL
to
Overweight
upgrade
$107 -> $119
2025-06-11
Reason
Wells Fargo
Price Target
$107 -> $119
2025-06-11
upgrade
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Insmed to $119 from $107 and keeps an Overweight rating on the shares. As the firm expected, the treprostinil palmitil inhalation powder Phase 2 readout is a clear win. The data significantly strengthened TPIP's potential to become the alternative/ go-to inhaled prostacyclin in pulmonary arterial hypertension, Wells adds.
BofA
Buy
maintain
$94 -> $109
2025-06-11
Reason
BofA
Price Target
$94 -> $109
2025-06-11
maintain
Buy
Reason
BofA raised the firm's price target on Insmed to $109 from $94 and keeps a Buy rating on the shares, citing "easily a best-case topline for treprostinil pro-drug TPIP that exceeded even our bullish outlook." The firm argues there's clear potential for TPIP to become "foundational" in pulmonary arterial hypertension PAH given the strength of the data and treprostinil's "well-established role in the paradigm." Following yesterday's update, the firm updated its model, raising its penetration rates and increasing its unadjusted 2035 sales forecasts to $3.4B from $2.0B, the analyst noted.
Mizuho
Graig Suvannavejh
Outperform
maintain
$96 -> $110
2025-06-11
Reason
Mizuho
Graig Suvannavejh
Price Target
$96 -> $110
2025-06-11
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Insmed to $110 from $96 and keeps an Outperform rating on the shares. The company reported positive Phase 2b data for treprostinil palmitil inhalation powder in pulmonary arterial hypertension, the analyst tells investors in a research note. The firm says the data "were outstanding," positioning TPIP as a potential new standard of care. Simply put, Insmed "hit a grand slam," contends Mizuho. The firm sees multiple opportunities for upside to estimates.
Morgan Stanley
Overweight
maintain
$90 -> $102
2025-06-11
Reason
Morgan Stanley
Price Target
$90 -> $102
2025-06-11
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Insmed to $102 from $90 and keeps an Overweight rating on the shares. Results from the Phase 2b trial evaluating treprostinil palmitil inhalation powder hit a "home run" scenario, showing significant efficacy across primary and secondary endpoints, the analyst tells investors. Following the data, the firm raised its view of the odds of success in pulmonary arterial hypertension to 85% from 55% and is boosting peak sales estimates "significantly."
See All Ratings
Valuation Metrics
The current forward P/E ratio for Insmed Inc (INSM.O) is -17.89, compared to its 5-year average forward P/E of -8.75. For a more detailed relative valuation and DCF analysis to assess Insmed Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.75
Current PE
-17.89
Overvalued PE
-4.72
Undervalued PE
-12.78
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-9.96
Current EV/EBITDA
-15.09
Overvalued EV/EBITDA
-5.68
Undervalued EV/EBITDA
-14.24
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
16.08
Current PS
23.76
Overvalued PS
24.48
Undervalued PS
7.68
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 264.45% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 264.45% over the last month.
Sold
Bought
INSM News & Events
Events Timeline
(ET)
2025-06-12
05:56:57
Insmed 7.812M share Spot Secondary priced at $96.00
2025-06-11 (ET)
2025-06-11
16:06:16
Insmed announces $650M common stock offering
2025-06-10 (ET)
2025-06-10
08:54:38
Liquidia falls after Insmed's TPIP meets endpoints in study
Sign Up For More Events
Sign Up For More Events
News
Preview
3.0
06-21NASDAQ.COMINSM Quantitative Stock Analysis
Preview
3.0
06-17NASDAQ.COMIs Insmed Stock Overvalued at $98?
Preview
2.0
06-15BenzingaOracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio?
Sign Up For More News
People Also Watch
FAQ
What is Insmed Inc (INSM) stock price today?
What is Insmed Inc (INSM)'s business?
What is the price predicton of INSM Stock?
What is Insmed Inc (INSM)'s revenue for the last quarter?
What is Insmed Inc (INSM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Insmed Inc (INSM)'s fundamentals?
How many employees does Insmed Inc (INSM). have?